Boyu Capital helps point Celgene-partnered Antengene down a quick path to commercialization
Shanghai-based Antengene has ushered in the first biotech mega-round of the year, designed to fuel a quick commercial turnaround of in-licensed cancer drugs.
The $120 million Series B marks a significant boost for the young biotech, which was founded in April 2017 on a deal with Celgene $CELG, and quite possibly the last financing round before Antengene heads to an IPO — according to previous comments by CEO Jay Mei.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.